( Data Published in Neurology Showed Tha...)Data on Higher Dose of Copaxone and Data Showing Copaxone is Most,Cost Effective,Health

Data Published in Neurology Showed That Higher Dose of Copaxone Increased Efficacy in Relapsing-remitting Multiple Sclerosis (RRMS)

Doubled Dose of COPAXONE Maintained Proven Safety Profile and Further Reduced Relapses and Lesions

JERUSALEM, Israel, April 17, 2007 – A 9-month, randomized, double-blind, parallel-group Phase II study of 90 patients comparing a 40 mg dose of COPAXONE given daily to the currently approved COPAXONE 20 mg dose showed a 38 percent greater reduction in inflammatory disease activity as measured by magnetic resonance images (MRI) of the brain. In addition, patients taking COPAXONE 40 mg experienced a reduced mean on-trial relapse rate of 77 percent when compared to annual relapse rate prior to entry, as compared to 62 percent with COPAXONE 20 mg.

The results of this study, entitled “Randomized, double-blind, dose-comparison of glatiramer acetate in relapsing-remitting MS,” were published in a recent issue of Neurology. The study can be accessed at: http://www.neurology.org/cgi/content/abstract/68/12/939.

"COPAXONE is an established RRMS therapy with more than 12 years of clinical research and experience supporting its efficacy and safety. The recently published data demonstrated that a 40

mg dose was well tolerated, with a safety profile similar to the currently available 20 mg dose," said Jeffrey A. Cohen, M.D., Director of the Experimental Therapeutics Program at Cleveland Clinic's Mellen Center for MS Treatment and Research and Coordinating Principal Investigator of the study. "In addition, the results suggested that a 40 mg dose of COPAXONE may provide better control of disease activity, and justify additional research on the therapeutic effect of higher dosages of this drug."

Based upon the
'"/>